Premium
Chitooligosaccharide Biguanidine Alleviates Liver Injury and Insulin Resistance in Type 2 Diabetic Rats
Author(s) -
Zhao Liyan,
Zheng Qifang,
Zou Yalu,
Wang Yuanyuan,
Wu Yuntang,
Liu Xiaofei
Publication year - 2020
Publication title -
starch ‐ stärke
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.62
H-Index - 82
eISSN - 1521-379X
pISSN - 0038-9056
DOI - 10.1002/star.201900203
Subject(s) - insulin resistance , medicine , endocrinology , glucokinase , insulin , streptozotocin , insulin receptor , insulin receptor substrate , irs1 , glutathione peroxidase , glucose transporter , phosphoenolpyruvate carboxykinase , chemistry , diabetes mellitus , superoxide dismutase , biochemistry , oxidative stress , enzyme
Chitooligosaccharide biguanidine (COSG) is a derivative of chitooligosaccharide that has been proven to have antidiabetic activity. In this study, the therapeutic effects of COSG on liver injury and insulin resistance are evaluated, and the possible mechanism is explored. Streptozotocin‐induced diabetic rats are treated with COSG for 8 weeks. COSG treatment significantly increases the activity of catalase, superoxide dismutase, and glutathione peroxidase and inhibits the activity of malonic dialdehyde. Histological observation reveals that COSG treatment also alleviates the probability of hepatocyte degeneration or necrosis. Furthermore, COSG treatment significantly activates the insulin receptor substrate‐2/phosphatidylinositol 3 kinase/protein kinase B signaling pathway and increases the glucose transporter 2/glucokinase expressions, which regulates liver glucose conversion and insulin secretion, COSG treatment also inhibits the glucose‐6‐phosphatase/phosphoenolpyruvate carboxykinase activations, resulting in a reduced level of blood glucose. Accordingly, COSG can protect against liver dysfunction caused by type 2 diabetes.